Concepedia

Klaus Bosslet

KB

Statistics

Publications

58

Citations

2.8K

H-Index

32

Active since

1979

Affiliations

Behringwerke (Germany)(Current)

Philipps University of Marburg

DKFZ-ZMBH Alliance

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology

Universität Hamburg

Klaus Bosslet is an author at Behringwerke (Germany) specializing in oncology, medicine, and pharmacology.

Publications per year

1979–2016

58

Publications

58

Elucidation of the mechanism enabling tumor selective prodrug monotherapy.

Klaus Bosslet, Rainer H. Straub, Matthias Blumrich et al. · PubMed · 1998 · 226 citations

Medicine, Oncology, Pharmacology +13

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker, Katharina Wartha, Thomas Friess et al. · Molecular Cancer Therapeutics · 2016 · 131 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17

Tumor-selective prodrug activation by fusion protein-mediated catalysis.

Klaus Bosslet, Jörg Czech, Dieter Hoffmann · PubMed · 1994 · 127 citations

Pharmacy, Oncology, Pharmacology +15

Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

Jin Gao, Jon Chesebrough, Susan A. Cartlidge et al. · Cancer Research · 2011 · 120 citations

Medicine, Cancer Biology, Oncology +16

Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes

Volker Schirrmacher, Klaus Bosslet, Geraldine D. Shantz et al. · International Journal of Cancer · 1979 · 114 citations

Life Sciences, Immunology, Oncology +17

1–5 of 58